Protocol Ledger

NCT07466017 · Phase II · ACTIVE NOT RECRUITING

A Study of CS060380 Tablets in Patients With MASH and Obesity

Interventional Phase II clinical trial protocol NCT07466017 sponsored by Cascade Pharmaceuticals in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-02 Enrollment: 130 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07466017
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)130 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07466017
Protocol FieldVerified Registry Value
NCT IdentifierNCT07466017
Consolidated Lead SponsorCascade Pharmaceuticals
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment130 participants (ACTUAL)
Registered Start Date2026-04-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI